|
|
Blood, 15 October 2006, Vol. 108, No. 8, pp. 2687-2694.
Prepublished online as a Blood First Edition Paper on July 6, 2006; DOI 10.1182/blood-2005-12-017319.
 Previous Article | Table of Contents | Next Article 
IMMUNOBIOLOGY
A role for BLyS in the activation of innate immune cells
Sook Kyung Chang,
Bonnie K. Arendt,
Jaime R. Darce,
Xiaosheng Wu, and
Diane F. Jelinek
From the Department of Immunology, Mayo Clinic College of Medicine, Rochester, MN.
B-lymphocyte stimulator (BLyS) is a member of the tumor necrosis factor (TNF) ligand superfamily. Although BLyS costimulates adaptive immune cells, the ability of BLyS to stimulate innate immune cells has not been described. Here, we show that BLyS strongly induces human monocyte survival, and activation as measured by proinflammatory cytokine secretion and up-regulation of costimulatory molecule expression. In addition, monocytes cultured with BLyS differentiated into macrophage-like cells. Regarding BLyS receptor(s) expression, freshly isolated monocytes bound low levels of exogenous BLyS and expressed primarily intracellular TACI, and cell surface TACI levels increased following monocyte activation. Of interest, bone marrow monocytes from some multiple myeloma patients expressed significant levels of cell surface TACI at isolation. Our findings indicate that BLyS plays a role in activating innate immune cells. Moreover, this study may explain more clearly why high BLyS production is often correlated with certain inflammatory autoimmune diseases and B-lymphocyte malignancies.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
K. Miura and Y. Rikihisa
Liver Transcriptome Profiles Associated with Strain-Specific Ehrlichia chaffeensis-Induced Hepatitis in SCID Mice
Infect. Immun.,
January 1, 2009;
77(1):
245 - 254.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D T La, C E Collins, H-T Yang, T-S Migone, and W Stohl
B lymphocyte stimulator expression in patients with rheumatoid arthritis treated with tumour necrosis factor {alpha} antagonists: differential effects between good and poor clinical responders
Ann Rheum Dis,
August 1, 2008;
67(8):
1132 - 1138.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. K. Chang, S. A. Mihalcik, and D. F. Jelinek
B Lymphocyte Stimulator Regulates Adaptive Immune Responses by Directly Promoting Dendritic Cell Maturation
J. Immunol.,
June 1, 2008;
180(11):
7394 - 7403.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. L. Langat, D. A. Wheaton, J. S. Platt, T. Sifers, and J. S. Hunt
Signaling Pathways for B Cell-Activating Factor (BAFF) and a Proliferation-Inducing Ligand (APRIL) in Human Placenta
Am. J. Pathol.,
May 1, 2008;
172(5):
1303 - 1311.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Schiffer, R. Bethunaickan, M. Ramanujam, W. Huang, M. Schiffer, H. Tao, M. M. Madaio, E. P. Bottinger, and A. Davidson
Activated Renal Macrophages Are Markers of Disease Onset and Disease Remission in Lupus Nephritis
J. Immunol.,
February 1, 2008;
180(3):
1938 - 1947.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. R. Darce, B. K. Arendt, S. K. Chang, and D. F. Jelinek
Divergent Effects of BAFF on Human Memory B Cell Differentiation into Ig-Secreting Cells
J. Immunol.,
May 1, 2007;
178(9):
5612 - 5622.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
